RIO DE JANEIRO, BRAZIL - Brazil’s health regulator Anvisa said on Tuesday, November 10th, that its decision to suspend trials for China’s Sinovac COVID-19 vaccine was purely technical and dismissed any “politicization” of its work to ensure a safe and effective vaccine.
“We had no choice but to suspend the trials given the event,” the head of the agency Antônio Barra Torres said at a news conference. Reuters reported . . .